Profile cover photo
Profile photo
Senesco Technologies, Inc.
6 followers -
Senesco Technologies (SNTID) is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancerous cells and protect healthy cells from premature death.
Senesco Technologies (SNTID) is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancerous cells and protect healthy cells from premature death.

6 followers
About
Senesco Technologies, Inc.'s posts

Post has attachment
The ALS Ice Bucket Challenge has increased awareness of patient advocacy around the world. Find out how you can become a Lymphoma Research Foundation advocate and the many ways you can make a difference in the lymphoma community. http://bit.ly/1C71AmC

Post has attachment
The diagnosis of multiple myeloma is often made incidentally during routine blood tests for other conditions. Learn more about diagnosing myeloma from the Multiple Myeloma Research Foundation here: http://bit.ly/1C71gV2

Post has attachment
Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
http://bit.ly/1u5tg61

Post has attachment
Tom Brokaw will be honored with the Spirit of Hope Award at the Multiple Myeloma Research Foundation annual gala. Brokaw was diagnosed with multiple myeloma in August of 2013. http://bit.ly/1u0V2AD

Post has attachment
Researchers at the University of Oslo have developed a new statistical method to determine at an early stage of lymphoma treatment which patients will develop an aggressive variant and when it will occur. This determination will allow doctors to initiate treatment early, or avoid burdensome treatment for those not at risk. http://bit.ly/1C70JCw

Post has attachment

Post has attachment
From his Houston Texans teammates and National Football League opponents to family members and fans, David Quessenberry has countless allies in his fight against non-Hodgkin’s lymphoma. “It’s overwhelming, and it motivates me to fight my fight even harder,” Quessenberry told http://on.today.com/yayDFJ. “I wake up every day knowing that I have an army behind me.” Read more here: http://on.today.com/1BC0LC6

Post has attachment
Doctors will perform many tests when Non-Hodgkin's Lymphoma is suspected. Learn about the plan of action here: http://bit.ly/1sO2XR2

Post has attachment
Phillip Tallmadge was 20 years old when he passed away from stage 1 Non-Hodgkins Lymphoma, less than 16 months after he was diagnosed. Throughout his illness, he posted updates on Facebook which left a lasting impression on his family and friends. After his passing, his brother shared Phillip's one last wish, encouraging his community to send flowers to someone simply out of kindness. The community reaction was overwhelming. Read the full article here: http://bit.ly/1BbuWA0

Post has attachment
Roche (ROG.VX), a biotech Company developing treatment options for breast, skin, colon, ovarian, lung and numerous other cancers announced on Monday that it will acquire Santaris Pharma, a privately-held Danish biotech company for up to $450 million in cash. Santaris develops drugs which work by blocking or "silencing" microRNAs, tiny strands of RNA, or ribonucleic acid, that help turn genes into proteins. This acquisition is an indication of a growing interest and confidence in siRNA-based drugs. http://reut.rs/1BbuSQP
Wait while more posts are being loaded